Biodegradable core-shell electrospun nanofibers containing bevacizumab to treat age-related macular degeneration

Souza, Sarah Oliveira Lamas de; Guerra, Maria Carolina Andrade; Heneine, Luíz Guilherme Dias; Oliveira, Carolina Reis de; Silva-Cunha, Armando; Fialho, Sílvia Ligório; Oréfice, Rodrigo Lambert

doi:10.1007/s10856-018-6187-5

Cited by 33 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Electrospinning has been recognized as a cost-effective, versatile, and useful laboratory method for the production of fibrous mats with large surface areas, and also with the possibility of scaling up [15,16,17,18,19]. In drug delivery, it has been investigated for the drug or probiotic incorporation into nanofibers [2,18,20,21], for the production of amorphous solid dispersions [22], taste masking [23] and as an alternative to the lyophilisation for the drying of the therapeutic proteins [24]. Electrospinning is also a rare nonthermal method that is suitable for the preparation of nanofibers from biopolymers, as these are sensitive to high temperatures [11].…”

Section: Introductionmentioning

confidence: 99%

Effect of Solution Composition Variables on Electrospun Alginate Nanofibers: Response Surface Analysis

2019

View full text Add to dashboard Cite

Alginate is a promising biocompatible and biodegradable polymer for production of nanofibers for drug delivery and tissue engineering. However, alginate is difficult to electrospin due to its polyelectrolyte nature. The aim was to improve the ‘electrospinability’ of alginate with addition of exceptionally high molecular weight poly(ethylene oxide) (PEO) as a co-polymer. The compositions of the polymer-blend solutions for electrospinning were varied for PEO molecular weight, total (alginate plus PEO) polymer concentration, and PEO proportion in the dry alginate–PEO polymer mix used. These were tested for rheology (viscosity, complex viscosity, storage and loss moduli) and conductivity, and the electrospun nanofibers were characterized by scanning electron microscopy. One-parameter-at-a-time approach and response surface methodology (RSM) were used to optimize the polymer-blend solution composition to obtain defined nanofibers. Both approaches revealed that the major influence on nanofiber formation and diameter were total polymer concentration and PEO proportion. These polymer-blend solutions of appropriate conductivity and viscosity enabled fine-tuning of nanofiber diameter. PEO molecular weight of 2–4 million Da greatly improved the electrospinnability of alginate, producing nanofibers with >85% alginate. This study shows that RSM can be used to design nanofibers with optimal alginate and co-polymer contents to provide efficient scaffold material for regenerative medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Solution Composition Variables on Electrospun Alginate Nanofibers: Response Surface Analysis

2019

View full text Add to dashboard Cite

show abstract

“…PCL and gelatin core-shell nanofibers loading BCZ at different concentrations (0.5, 1, 2, and 4 wt%) showed similar diameters of nanofibers (224, 244, 272, and 255 nm, respectively). BCZ was cumulative released from the nanofibers in a deionized water medium, proportional to the amount of BCZ initially incorporated into the nanofibers within 6 days [ 61 ]. Self-associated BCZ nanoparticles have been prepared at the isoelectric point of BCZ (pH 8.4) using nonionic surfactants (polysorbate 80, polysorbate 20, or polyoxyethylene-10-oleyl-ether) to stabilize and protect the BCZ from denaturation and degradation [ 62 ].…”

Section: Development Of Nanoparticulate Drug Delivery Systems For Bczmentioning

confidence: 99%

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

et al. 2021

View full text Add to dashboard Cite

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.

show abstract

“…The in vitro half-life was 11.4 ± 4.4 days and 52.9 ± 14.8 days for F beva and F bevaP , respectively [ 296 ]. Biodegradable core-shell electrospun nanofibers of bevacizumab were designed by de Souza et al [ 297 ]. The nanofiber shells were synthesised from gelatin and PCL, with a PVA core protecting and storing bevacizumab.…”

Section: Polypeptide Deliverymentioning

confidence: 99%

“…The nanofiber shells were synthesised from gelatin and PCL, with a PVA core protecting and storing bevacizumab. No cell toxicity was observed, and the formulation maintained anti-angiogenic properties and displayed a slow release [ 297 ].…”

Section: Polypeptide Deliverymentioning

confidence: 99%

Injectables and Depots to Prolong Drug Action of Proteins and Peptides

et al. 2020

View full text Add to dashboard Cite

Proteins and peptides have emerged in recent years to treat a wide range of multifaceted diseases such as cancer, diabetes and inflammation. The emergence of polypeptides has yielded advancements in the fields of biopharmaceutical production and formulation. Polypeptides often display poor pharmacokinetics, limited permeability across biological barriers, suboptimal biodistribution, and some proclivity for immunogenicity. Frequent administration of polypeptides is generally required to maintain adequate therapeutic levels, which can limit efficacy and compliance while increasing adverse reactions. Many strategies to increase the duration of action of therapeutic polypeptides have been described with many clinical products having been developed. This review describes approaches to optimise polypeptide delivery organised by the commonly used routes of administration. Future innovations in formulation may hold the key to the continued successful development of proteins and peptides with optimal clinical properties.

show abstract

Biodegradable core-shell electrospun nanofibers containing bevacizumab to treat age-related macular degeneration

Cited by 33 publications

References 15 publications

Effect of Solution Composition Variables on Electrospun Alginate Nanofibers: Response Surface Analysis

Effect of Solution Composition Variables on Electrospun Alginate Nanofibers: Response Surface Analysis

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Injectables and Depots to Prolong Drug Action of Proteins and Peptides

Contact Info

Product

Resources

About